# The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients

> **NCT02822534** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** SP2086

## Key facts

- **NCT ID:** NCT02822534
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2016-07
- **Final completion:** —
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2016-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02822534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02822534, "The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02822534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*